0001415889-24-002412.txt : 20240202
0001415889-24-002412.hdr.sgml : 20240202
20240202212821
ACCESSION NUMBER: 0001415889-24-002412
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howe Jolanda
CENTRAL INDEX KEY: 0001974200
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38981
FILM NUMBER: 24593705
MAIL ADDRESS:
STREET 1: C/O MIRUM PHARMACEUTICALS, INC.
STREET 2: 950 TOWER LANE, SUITE 1050
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001759425
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831281555
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 1050
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 650-667-4085
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 1050
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
form4-02032024_020214.xml
X0508
4
2024-01-31
0001759425
Mirum Pharmaceuticals, Inc.
MIRM
0001974200
Howe Jolanda
C/O MIRUM PHARMACEUTICALS, INC.
950 TOWER LANE, SUITE 1050
FOSTER CITY
CA
94404
false
true
false
false
SVP, GLOBAL CONTROLLER
0
Common Stock
2024-01-31
4
M
0
1772
A
2494
D
Common Stock
2024-02-02
4
S
0
735
26.1918
D
1759
D
Restricted Stock Units
2024-01-31
4
M
0
1772
0
D
Common Stock
1772
3543
D
Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares will vest January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026.
/s/ Judit Ryvkin, Attorney-in-Fact
2024-02-02